Inhibitor of MAP kinase activation blocks colon cancer growth

Slides:

Advertisements

Similar presentations

Waging War on Cancer with the Sword of Immunity Cell Volume 158, Issue 2, (July 2014) DOI: /j.cell Copyright © 2014 Terms and Conditions.

Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

Extracellular Environment. Extracellular Environment.

The Good Fat Cell Volume 147, Issue 7, (December 2011) DOI: /j.cell Copyright © 2011 Terms and Conditions Terms and Conditions.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD suppresses expression of prometastasis phenotypes in malignant pleural.

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Chap. 16 Problem 1 Cytokine receptors and RTKs both form functional dimers on binding of ligand. Ligand binding activates cytosolic kinase domains which.

Volume 68, Issue 1, Pages (July 2015)

BRAF inhibitor: targeted therapy in hairy cell leukemia

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

Volume 114, Issue 2, Pages (February 1998)

Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor Suzanne M. Nicholl,

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

New class of anti-inflammatory agents for colonic epithelial cells

Volume 116, Issue 5, Pages (May 1999)

Killing Tumors by Keeping Ras and PI3′ Kinase Apart

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

GLP-1–Based Therapies: The Dilemma of Uncertainty

Michèle Algarté-Génin, Olivier Cussenot, Pierre Costa European Urology

Jing Zhang, Thomas M. Roberts, Ramesh A. Shivdasani Gastroenterology

Gastroenterology news

Volume 153, Issue 3, Pages e16-e17 (September 2017)

Volume 131, Issue 5, Pages (November 2006)

In This Issue Cell Volume 158, Issue 5, (August 2014)

A genome-based strategy uncovers frequent BRAF mutations in melanoma

Toru Furukawa Clinical Gastroenterology and Hepatology

Hepatitis B “X” gene linked to cellular calcium release

PTEN Enters the Nuclear Age

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Volume 131, Issue 5, Pages (November 2006)

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Janus Kinase Deregulation in Leukemia and Lymphoma

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Vascular Endothelial Growth Factor (VEGF) Pathway

Volume 152, Issue 1, (January 2013)

A Mediator Lost in the War on Cancer

The RAF Inhibitor Paradox Revisited

Activity-Based Profiling for Drug Discovery

Clinical courses of patients.

Volume 130, Issue 6, (September 2007)

Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

Volume 143, Issue 6, (December 2010)

Conspiracy Theory Cell

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

NF-κB/Rel/IκB: Implications in gastrointestinal diseases

Cancer and Inflammation: An Aspirin a Day Keeps the Cancer at Bay

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Regina M. Vidaver, PhD, Beth S. Schachter, PhD

The new kid on the block(ade) of the IGF-1 receptor

Volume 56, Issue 6, Pages (December 1999)

Mutant BRAF Melanomas—Dependence and Resistance

Volume 163, Issue 4, (November 2015)

Volume 163, Issue 2, (October 2015)

by Jennifer Couzin-Frankel

Angiomyolipoma of the Colon

Simplified BRAF signaling network.

Volume 134, Issue 6, (September 2008)

In This Issue Cell Volume 145, Issue 3, (April 2011)

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Airway smooth muscle: A modulator of airway remodeling in asthma

Volume 148, Issue 1, (January 2012)

Presentation transcript:

Inhibitor of MAP kinase activation blocks colon cancer growth Dan Gordon Gastroenterology Volume 117, Issue 3, (September 1999) DOI: 10.1016/S0016-5085(99)70436-1 Copyright © 1999 Terms and Conditions

Fig. 1 PD 184352, a potent, highly specific, and orally active inhibitor of MEK (MAP kinase kinase) acts at a critical convergence point through which receptor tyrosine kinases (RTK) and G protein-coupled receptors (GPCR) activate MAP kinase and stimulate multiple downstream effects including tumor cell proliferation. Gastroenterology 1999 117, DOI: (10.1016/S0016-5085(99)70436-1) Copyright © 1999 Terms and Conditions